Prostate Cancer Precision Therapy Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Prostate Cancer Precision Therapy Dream Team

SU2C−Prostate Cancer Foundation Prostate Dream Team:
Precision Therapy of Advanced Prostate Cancer

Grant Term: August 2012−July 2016

Recent studies have demonstrated tremendous diversity in the genetic makeup of metastatic castration-resistant prostate cancer (mCRPC). The SU2C−Prostate Cancer Foundation (PCF) Prostate Dream Team is sequencing patient DNA and systematically comparing it with patient response to therapies. The aim is to identify biomarkers and predictors that will help physicians determine the best treatments for patients based on their molecular profiles.


The SU2C−PCF Prostate Dream Team hypothesizes that the molecular qualities of a patient’s castration-resistant prostate cancer can guide the doctor in choosing a treatment that is best tailored to the patient. To advance this precision therapy, researchers have implemented a multicenter study that systematically evaluates patients enrolling in four clinical trials for CRPC, identified predictors of response, and identified predictors of resistance.


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.